ChEMBL ligand: CHEMBL3890942
Acyl coenzyme A:cholesterol acyltransferase 1 in Human [ChEMBL: CHEMBL2782] [UniProtKB: P35610] There should be some charts here, you may need to enable JavaScript!
acetyl-CoA acetyltransferase 1 in Human [GtoPdb: 2435] [UniProtKB: P24752] There should be some charts here, you may need to enable JavaScript!
acetyl-CoA acetyltransferase 2 in Human [GtoPdb: 2436] [UniProtKB: Q9BWD1] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
Acyl coenzyme A:cholesterol acyltransferase 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2782] [UniProtKB: P35610]
ChEMBL	Inhibition of human ACAT1	B	6.35	pIC50	450	nM	IC50	US-20140308340-A1. Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases (2014)
ChEMBL	Inhibition Assay: Methods for assessing the selectively of ACAT1 inhibitors are known in the art and can be based upon any conventional assay including, but not limited to the determination of the half maximal (50%) inhibitory concentration (IC) of a substance (i.e., 50% IC, or IC50), the binding affinity of the inhibitor (i.e., Ki), and/or the half maximal effective concentration (EC50) of the inhibitor for ACAT1 as compared to ACAT2. See, e.g., Lada, et al. (2004) J. Lipid Res. 45:378-386 and U.S. Pat. No. 5,968,749. ACAT1 and ACAT2 proteins that can be employed in such assays are well-known in the art and set forth, e.g., in GENBANK Accession Nos. NP-000010 (human ACAT1) and NP-005882 (human ACAT2). See also U.S. Pat. No. 5,834,283.	B	6.35	pIC50	450	nM	IC50	US-9149492-B2. Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease (2015)
acetyl-CoA acetyltransferase 1 in Human [GtoPdb: 2435] [UniProtKB: P24752]
GtoPdb	-	-	6.35	pIC50	450	nM	IC50	Atherosclerosis (2007) 191: 290-7 [PMID:16820149]
acetyl-CoA acetyltransferase 2 in Human [GtoPdb: 2436] [UniProtKB: Q9BWD1]
GtoPdb	-	-	3.89	pIC50	130000	nM	IC50	Atherosclerosis (2007) 191: 290-7 [PMID:16820149]

ChEMBL data shown on this page come from version 33:

Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]